© 2000 American Heart Association, Inc.
Thrombosis |
Hypoxia Induces Transcription of the Plasminogen Activator Inhibitor-1 Gene Through Genistein-Sensitive Tyrosine Kinase Pathways in Vascular Endothelial Cells
From the Second Department of Internal Medicine, Gunma University School of Medicine (T. Uchiyama, M.K., Y.O., T. Utsugi, N.A., M.S., R.N.), and the School of Health Science, Faculty of Medicine, Gunma University (S.T.), Gunma; Saitama Medical Center, Saitama Medical School (S.K.), Saitama; and the Department of Cardiovascular Disease, Graduate School of Medicine, University of Tokyo (R.N.), Tokyo, Japan.
Correspondence to Masahiko Kurabayashi, MD, Second Department of Internal Medicine, Gunma University School of Medicine, 3-39-15, Showa-machi, Maebashi, 371-8511, Japan.
 |
Abstract |
|---|
 Top Abstract IntroductionMethodsResultsDiscussionReferences |
|---|
Abstract—A decline in oxygen concentration perturbs endothelial function, which promotes local thrombosis. In this study, we determined whether hypoxia in the range of that observed in pathophysiological hypoxic states stimulates plasminogen activator inhibitor-1 (PAI-1) production in bovine aortic endothelial cells. PAI-1 production, measured by ELISA, was increased by 4.7-fold (P<0.05 versus normoxic control, n=4) at 12 hours after hypoxic stimulation. Northern blot analysis showed the progressive time-dependent increase in the steady-state level of PAI-1 mRNA expression by hypoxia, which reached a 7.5-fold increase (P<0.05 versus control, n=4) at 12 hours. Deferoxamine, which has been known to bind heme protein and to reproduce the hypoxic response, induced PAI-1 production at both the mRNA and protein levels. The half-life of PAI-1 mRNA, as determined by a standard decay assay, was not affected by hypoxia, suggesting that induction of PAI-1 mRNA was regulated mainly at the transcriptional level. Transient transfection assays of the human PAI-1 promoter–luciferase construct indicates that a hypoxia-responsive region lies between -414 and -107 relative to the transcription start site, where no putative hypoxia response element is found. The hypoxia-mediated increase in PAI-1 mRNA levels was attenuated by the tyrosine kinase inhibitors genistein (50 µmol/L) and herbimycin A (1 µmol/L), whereas PD98059 (50 µmol/L, MEK1 inhibitor), SB203580 (10 µmol/L, p38 mitogen-activated protein kinase inhibitor), and calphostin C (1 µmol/L, protein kinase C inhibitor) had no effect on the induction of PAI-1 expression by hypoxia and deferoxamine. Genistein but not daidzein blocked the production of hypoxia- and deferoxamine-induced PAI-1 protein. Thus, we conclude that hypoxia stimulates PAI-1 gene transcription and protein production through a signaling pathway involving genistein-sensitive tyrosine kinases in vascular endothelial cells.
Key Words: hypoxia • PAI-1 • tyrosine kinase • mitogen-activated protein kinase • endothelial cells
|
Introduction |
|---|
|
TopAbstractIntroductionMethodsResultsDiscussionReferences |
|---|
There is growing evidence indicating that vascular endothelium plays an obligatory role in regulating fibrinolytic activity, such as vascular tone and platelet activity.1 Endothelial dysfunction leads to the derangement of vascular endothelial anticoagulant properties and contributes to the pathophysiology of several cardiovascular disorders, including intravascular thrombosis, intimal growth, and plaque rupture.2
Endothelial cells have been shown to produce many vasoactive substances that intervene in the fibrinolysis and coagulation processes. Of the many components regulating the balance between procoagulant and anticoagulant properties of the endothelium, pathways controlling plasminogen activator activity are particularly important. This activity is controlled primarily by plasminogen activator inhibitor-1 (PAI-1), which is synthesized by endothelial cells,3 smooth muscle cells,4 5 platelets,6 monocytes,7 and hepatocytes.8 Increased levels of PAI-1 activity resulting in decreased fibrinolytic capacity have been reported in patients with coronary artery disease and metabolic syndrome of insulin resistance.9 In addition, increased PAI-1 levels have also been demonstrated in atherosclerotic lesions within the vessel wall.10 Therefore, both systemically and locally increased PAI-1 concentrations could have a pathogenic role in the development of atherosclerotic disease.
PAI-1 synthesis has been shown to be regulated by a number of relevant factors, including endotoxin, inflammatory cytokines,11 lipoprotein,12 angiotensin II,13 transforming growth factor-ß,14 and phorbol ester15 in endothelial cells, and by low oxygen levels (hypoxia) in trophoblasts.16 Hypoxia is often associated with thrombosis, which is a major cause of morbidity and mortality and can appear in many clinical contexts. For example, pulmonary emboli seem to be a common complication in acute respiratory failure.17 In addition, stasis of blood, a condition that, if severe enough, causes a decline in oxygen tension, predisposes to the development of thrombosis. Despite the well-appreciated association between hypoxia and thrombosis, the precise molecular mechanism of prothrombotic diathesis under hypoxic conditions remains unknown. We hypothesize that hypoxia induces PAI-1 expression, which contributes to the predisposition to thrombosis.
In this study, we examined whether hypoxia in the range of that observed in pathophysiological hypoxic states induces PAI-1 expression in endothelial cells. Furthermore, we investigated the molecular mechanisms underlying the increased production of PAI-1 in endothelial cells in response to hypoxia. Our results showed that hypoxia stimulates transcription from the PAI-1 promoter gene via genistein-sensitive tyrosine kinase–dependent pathways. Promoter analysis by transient transfection assays delineated the hypoxia response region between -414 and -107, which contains no canonical hypoxia response element (HRE). These findings emphasize the role of tyrosine kinases in transducing the hypoxic signals to nuclei and provide new insights into the pathogenesis of thrombosis originating from vascular disorders in which oxygen tensions are decreased.
|
Methods |
|---|
|
TopAbstractIntroductionMethodsResultsDiscussionReferences |
|---|
Materials
The hypoxic chamber and Anaeropack (disposable agent)18 were purchased from Mitsubishi Gas Chemical. PD98059, SB203580, calphostin C, genistein, herbimycin A, and tyrphostin 23 (RG-50810) were purchased from Calbiochem. RPMI-1640 medium, FCS, streptomycin, and penicillin were purchased from Gibco-BRL. A random primer kit was purchased from Boehringer Mannheim. Deferoxamine was purchased from Sigma. [
-32P]dCTP (3000 Ci/mmol) was obtained
from Amersham.
Cell Culture
Bovine aortic endothelial cells (BAECs) were
isolated, as previously described, by mechanical scraping of the intima
of the descending bovine aortas.19 The cells were plated
at a density of 105 cells on 10-cm plastic Petri
dishes. The cells were cultured at 37°C in RPMI-1640 medium
supplemented with 10% FCS, 50 U/mL penicillin, and 50 mg/mL
streptomycin.
Hypoxia
The hypoxic condition was achieved by use of an
anaerobic jar equipped with Anaeropack as previously
described (disposable aerating agent, Mitsubishi Gas
Chemical).18 20 21 Intracellular hypoxia was
generated by deferoxamine (130 µmol/L).
RNA Extraction and Northern Blot Analysis
Total cellular RNA was isolated from BAECs with Isogen
(Nippon Gene) as described previously.22 Equal amounts of
RNA were resolved by electrophoresis on 1.2% agarose gel containing
25 mmol/L MOPS buffer (pH 7.0), 1 mmol/L EDTA, and 2.2 mol/L
formaldehyde and were transferred onto Hybond N+ nylon membranes
(Amersham Corp) according to the methods suggested by the manufacturer.
The membranes were optimally cross-linked with UV light (Stratagene)
and hybridized for 14 hours at 42°C with a specific cDNA probe
radiolabeled with [-32P]dCTP (Amersham) in
hybridization buffer containing 40% formamide, 5xSSC, 1% SDS, and
100 mg/mL denatured salmon sperm DNA. The cDNA clone for PAI-1 was
obtained by polymerase chain reaction (PCR) with the forward primer
5'-ACAAGGGCATGGCCCCCGCCCTCCGGCATC-3' and reverse primer
5'-TTTGTGTGTGTCTTCACCCAGTCATTGATG-3', which are designed to amplify a
DNA sequence containing the human PAI-1 exon 2.23 The cDNA
for endothelial nitric oxide synthase (eNOS) was
obtained by PCR with the forward primer
5'-CTGGCCAAG-GTGACCATCGTGGACCACCAC-3' and reverse primer
5'-GTTGGCCACTTCCTTAAAGGTCTTCTTCCT-3', which are designed to amplify a
DNA sequence containing the bovine eNOS exon 11, intron 11, and exon
12.24 These PCR products were ligated to TA
vector and sequenced. Radiolabeling of the probes, a 233-bp fragment of
human PAI-1 cDNA sequence and a 384-bp fragment of bovine
endothelial NOS cDNA, was performed with a random
primer labeling kit according to the manufacturer’s protocol. After
hybridization, the filters were washed under conditions of high
stringency in 0.1xSSC containing 1% SDS.
Autoradiography was performed with the intensifying
screen and Kodak XAR5 film at -80°C for 3 to 5 days.
Promoter-Luciferase Vector and Expression Plasmid
For generation of PAI-1 promoter luciferase reporter genes, the
following forward primers and reverse primer were used in a PCR
reaction using a plasmid containing an 
3.4-kb DNA insert (courtesy
of Dr Douglas E. Vaughan, Vanderbilt University Medical Center,
Nashville, Tenn) as a template.25
Sequences for PCR forward primers with a KpnI site
(italicized) were nt-414,
5'-CCCGGTACCTGGTTCGCCAAAGGAAAAGCA-3' and nt-107,
5-CCCGGTACCTGTTCAGACGGACTCCCAGAG-3'; the reverse primer (nt
+82) with a XhoI site (italicized) was
5'-GGGCTCGAG-CTGCAGGAATTCCGATGCTGG-3'. PCR products
were gel-purified, digested, and subcloned into the
KpnI/XhoI sites of the promoterless luciferase
reporter gene vector pGL3-Basic (Promega). The expression plasmid for
hypoxia-inducible factor (HIF)-1–like factor (HLF) has been
described.26
PAI-1 Production
PAI-1 production was evaluated with a commercially
available ELISA kit (American Diagnostica Inc). Briefly,
cells were grown on 6-cm dishes to 80% confluence in RPMI-1640
supplemented with 10% FCS, and medium was switched to serum-free
RPMI-1640 before the cells were exposed to hypoxia. Culture
supernatants were removed after 12 hours, and PAI-1 production,
normalized to cellular protein concentrations, was evaluated.
DNA Transfection and Luciferase Assay
DNA transfections into cultured BAECs were performed by using
Tfx-50 (Promega) according to the manufacturer’s procedure. Cells were
transfected with 1 µg of reporter plasmid or transfected with 1 µg
of reporter plasmid and 2 µg of expression vector. After
transfection, cultures were maintained with RPMI-1640 containing
10% FCS. Luciferase activity was measured with a Berthold Lumat LB9501
luminometer and was normalized to cellular protein concentrations. Each
transfection was repeated at least 3 times in duplicate.
Data Analysis
Data are presented as the mean±SEM for 
3 separate
experiments. Statistical analysis was performed with a paired
Student’s t test, with significant differences determined
as P<0.05.
|
Results |
|---|
|
TopAbstractIntroductionMethodsResultsDiscussionReferences |
|---|
Hypoxia Upregulated PAI-1 Production by BAECs
To investigate whether hypoxia at physiological levels directly affects homeostasis in endothelial culture, we used the Anaeropack, which is a disposable oxygen–absorbing and CO2 (
5%)–generating agent. Under our experimental conditions, oxygen
tension within the culture medium dropped to 53.7±9.1 mm Hg
after 4 hours and remained unchanged thereafter in the presence of
Anaeropack; oxygen tension was 52.2±7.3 mm Hg after 6 hours and
53.6±8.4 mm Hg after 12 hours of incubation. There were no
detectable variations in cell morphology at the microscopic level
between cells exposed to ambient air and cells maintained in the
hypoxic chamber (data not shown). Under these conditions, BAECs were
cultured for 12 hours and tested for PAI-1 production with
ELISA. As shown in Figure 1A
, exposure to
hypoxia significantly (P<0.01, n=4) increased PAI-1
production in a time-dependent manner. To determine whether the
observed increase represents an upregulation in PAI-1 mRNA
expression, Northern blot analysis was performed. BAECs were
harvested for RNA analysis at the indicated times after hypoxic
stimulation. As shown in Figure 1, B and C, progressive
time-dependent increases in PAI-1 mRNA levels were observed in cells
cultured in hypoxic conditions, whereas ß-actin mRNA levels were only
modestly changed. Induction of PAI-1 mRNA levels was evident by 4 hours
and reached a maximum by 12 hours. In contrast, tissue-type
plasminogen activator (tPA) and urokinase-like
PA (uPA) mRNA levels were not noticeably induced in response to
hypoxia (data not shown).
|
To assess the possible involvement of heme proteins in the regulation
of PAI-1 expression by hypoxia, the effects of
deferoxamine on the PAI-1 mRNA levels were examined because
this reagent is known to prevent binding of molecular oxygen to heme
proteins and thus reproduce the hypoxic response.27
Exposure of BAECs to deferoxamine led to a smaller but
consistent increase in both PAI-1 protein and mRNA levels
(Figure 2, A and B).
|
Hypoxia Increased PAI-1 mRNA Expression at the
Transcriptional Levels
To determine whether hypoxia increases steady-state levels
of PAI-1 mRNA at the transcriptional level or posttranscriptional level
involving, for example, decreased degradation rate, measurement of
PAI-1 mRNA half-life was performed in the presence or absence of
actinomycin D (5 µg/mL). The results show that there is no
significant difference in the half-life of PAI-1 mRNA between the
absence and the presence of hypoxia or deferoxamine
(Figure 3, A and B). Thus,
hypoxia does not appear to affect the stability of PAI-1 mRNA,
suggesting that the observed increase in PAI-1 mRNA levels by
hypoxia was due to an increase in transcription from the PAI-1
promoter. It is also interesting to note that the stability of PAI-1
mRNA is considerably higher than that of eNOS mRNA, because eNOS mRNA
levels were decreased by 80% of control at 10 hours after treatment
with actinomycin D.
|
Hypoxia Increased PAI-1 Promoter Activity
We then performed transient transfection assays to test whether
hypoxia stimulates transcription from the PAI-1 promoter. The
human PAI-1 promoter, which contains 414 bp of the 5'-flanking region
and 80 bp of the 5'-untranslated region, was linked to the luciferase
gene, and the resultant construct, -414PAI-1Luc, was
transiently transfected into BAECs. Exposure of the cells to
hypoxia for 12 hours increased luciferase activity modestly but
reproducibly (2.0±0.1-fold, P<0.05 compared with normoxia,
n=8) (Figure 4A). To verify the
specificity of an increase in luciferase activity, ß-actin promoter
luciferase construct was transfected into BAECs, and luciferase
activity was measured in the same way. No significant change was
observed in luciferase activity from the ß-actin promoter, thus
suggesting that the induction of -414PAI-1Luc activity by
hypoxia is promoter-specific. Transcriptional activation of
PAI-1 promoter by deferoxamine was also examined by
transient transfection assays. Incubation of transfected cells with
deferoxamine (130 µmol/L) increased luciferase
activity derived from the -414PAI-1Luc construct, whereas ß-actin
promoter activity was not affected by deferoxamine (Figure 4B). Deletion to -107 significantly attenuated the induction of
promoter activity in response to hypoxia, thus indicating that
the hypoxia-mediated increase in PAI-1 promoter activity is
mediated at least partly through the sequence between -414 and -107.
Because no canonical HRE (5'-RCGTG-3')28 was
found within this region, these data suggest that hypoxia
induces PAI-1 promoter activity through HRE-independent
cis-regulatory elements.
|
Hypoxia-Induced PAI-1 mRNA Expression Was Mediated Through
Tyrosine Kinase–Dependent Pathway
To determine the signal transduction pathways that play a major
role in inducing PAI-1 mRNA expression, we examined the effects of a
variety of protein kinase inhibitors on the steady-state
levels of PAI-1 mRNA. We used the inhibitors at the
concentrations that have been proved to be effective in blocking the
phosphorylation of the substrates.29 As
shown in Figure 5, pretreatment of BAECs
with the protein kinase C inhibitor calphostin C (1
µmol/L) or the mitogen-activated protein kinase
(MAP)/extracellular signal-regulated kinase (ERK) (MEK)1-specific
inhibitor PD98059 (50 µmol/L) had no effects on
either basal or hypoxia-stimulated increases in PAI-1 mRNA
levels. In contrast, pretreatment of BAECs with SB203580 (10
µmol/L), a specific inhibitor for p38 MAP kinase, led to
a significant decrease in basal PAI-1 mRNA levels, whereas it had
little effect on the multiples of induction of hypoxia-mediated
PAI-1 mRNA levels. Conversely, the nonselective tyrosine kinase
inhibitor genistein (50 µmol/L),30 but
not daidzein (negative control of genistein), reduced both basal and
hypoxia-stimulated increases in PAI-1 mRNA expression.
Likewise, herbimycin A (1 µmol/L), which irreversibly inhibits
the nonreceptor tyrosine kinases, including Src31 and
Bcr-Abl,32 reduced the basal and hypoxia-induced
PAI-1 mRNA levels. Tyrphostin 23 (100 µmol/L), which potently
inhibits epidermal growth factor (EGF) receptor tyrosine
kinases,33 reduced basal levels of PAI-1 mRNA but had no
effect on the induction of PAI-1 expression by hypoxia. These
results indicate that genistein and herbimycin A are effective in
reducing both basal and hypoxia-stimulated PAI-1 mRNA
expression and that p38 MAP kinase plays a role in maintaining the
basal expression of PAI-1 mRNA but does not play a major role in
inducing PAI-1 mRNA in response to hypoxia. As shown in Figure 6, studies with deferoxamine
showed the same results as those observed in hypoxic stimulation:
SB203580, genistein, and herbimycin A led to a significant drop in
basal PAI-1 mRNA expression, and genistein and herbimycin A but not
SB203580 prevented hypoxia-mediated increases in PAI-1 mRNA
expression.
|
|
Genistein Inhibited Hypoxia-Mediated PAI-1 Protein
Production
The effects of genistein on hypoxia-induced PAI-1 protein
were examined with ELISA (Figure 7). The
results show that increased production of PAI-1 in response to
hypoxia is blunted in the presence of genistein, whereas
daidzein had little inhibitory effect on this response.
Calphostin C, PD98059, and SB203580 appeared to attenuate the hypoxic
response but did not play a major role in preventing the induction of
PAI-1 protein by hypoxia.
|
HLF Induced PAI-1 Promoter
We next examined whether PAI-1 promoter is regulated by HLF, a
transcription factor that has been shown to be involved in gene
expression in response to hypoxia. As shown in Figure 8, cotransfection of expression vector
for HLF (pBOS-HLF) along with the PAI-1 promoter–luciferase constructs
showed that HLF increased the luciferase activity derived from
-414PAI-1Luc but not from -107PAI-1Luc. These findings were
consistent with the results in Figure 4
, in which
-414PAI-1Luc but not -107PAI-1Luc was responsive to hypoxia.
The promoter of ß-actin gene was not affected by pBOS-HLF, further
indicating that the response of PAI-1 promoter to pBOS-HLF was
promoter-specific.
|
|
Discussion |
|---|
|
TopAbstractIntroductionMethodsResultsDiscussionReferences |
|---|
Although there has been an increasing appreciation for the role of oxygen tension in regulating endothelial function, little is known about the molecular mechanisms responsible for the alteration in gene expression by hypoxia in endothelial cells. In this study, we investigated the effects of hypoxia on PAI-1 gene expression in BAECs in a hypoxic chamber in which oxygen tension was decreased to a level observed in pathophysiological conditions. One of the major conclusions drawn from this study was that the physiological range of low oxygen tension is sufficient to induce PAI-1 mRNA expression at the transcriptional level in endothelial cells.
Previous studies on the effects of hypoxia on PAI-1 expression have yielded conflicting results. Wojta et al34 showed that exposure of bovine lung endothelial cells increases PAI-1 activity, but they claimed that this response is due to the impaired release of plasminogen activator with a consequent increase in the levels of available PAI-1. Studies by Bach et al35 showed a decrease in PAI-1 activity in anoxic cultures of human umbilical vein endothelial cells and a concomitant increase in tPA activity.36 Our data are consistent with a recent report in which PAI-1 mRNA was increased in response to hypoxia in trophoblastic cells.16 To the best of our knowledge, the present work is the first demonstration that reduced oxygen tension led to an increase in PAI-1 mRNA expression in endothelial cells. In contrast to PAI-1 induction, tPA and uPA mRNA levels were not noticeably induced in response to hypoxia, which suggests that hypoxia increases procoagulant activity without increasing anticoagulant activity.
We demonstrated that genistein-sensitive tyrosine kinase is involved in hypoxia-induced PAI-1 expression. Although genistein is a broad-spectrum tyrosine kinase inhibitor, the effect of genistein on PAI-1 expression was rather selective because another tyrosine kinase inhibitor, tyrphostin 23, had no effect. The importance of tyrosine kinases in signal transduction by hypoxia has been well documented. In the nitrogen-fixing gene in the bacterium Rhizobium meliloti, hypoxia induces oxygen dissociation from the heme group, which activates tyrosine kinase and results in the phosphorylation of transcription factors.37 In higher organisms, Mukhopadhyay et al38 reported that hypoxia activates pp60c-src, which, in turn, phosphorylates downstream transcription factors responsible for the hypoxic induction of vascular EGF (VEGF). Because genistein is an inhibitor of pp60c-src,39 these mechanisms appear to conform to our findings. Further studies will be necessary to test the role of pp60c-src in inducing PAI-1 gene expression in response to hypoxia.
In this study, a MEK1 inhibitor, PD98059, had no effects on hypoxia-mediated induction of PAI-1 mRNA levels. This finding was somewhat surprising, because previous studies have demonstrated that activation of the ERK/MAP kinase cascade is implicated in the hypoxic response. Mukhopadhyay et al38 documented that a plasmid-overexpressing dominant negative form of Raf-1 mutant or the ERK inhibitor 6-thioguanine clearly inhibit the hypoxia-mediated increase in VEGF mRNA levels. Muller et al40 reported the induction of c-fos gene transcription through a MAP kinase–dependent pathway in HeLa cells. Although a variety of stimuli, including phorbol ester, endothelin-1,41 transforming growth factor-ß,14 and high glucose,25 induce PAI-1 mRNA expression, little evidence exists for the role of ERK/MAP kinase pathways in the inducible expression of the PAI-1 gene. Consistent with these results, we found that overexpression of a constitutive active mutant of MEK1 had only minimal effects on PAI-1 promoter activity (T. Uchiyama, M. Kurabayashi, and R. Nagai, unpublished results). These findings may account for the inability of MEK1 inhibitor to block the inducible expression of the PAI-1 gene in response to hypoxia.
Deletion analysis of PAI-1 promoter indicated that the region spanning between -414 and -107 contains element(s) mediating the hypoxic response. In agreement with these results, forced expression of HLF markedly induces luciferase activity of -414PAI-1Luc but not that of -107PAI-1Luc. A search for the putative transcription factor–binding sites within this region revealed that it contains an AP-1–like site (TGGGTCA) at -54, a CAGA box (AGACAGACA) at -190 and -290, and an E-box (CAATTG) at -153 and -214.42 However, no consensus HRE was found in this region. Further studies will be necessary to understand the mechanisms underlying the HRE-independent induction of PAI-1 promoter by HLF.
In conclusion, the present study showed that PAI-1 production was significantly induced in response to a physiological range of hypoxic conditions at the mRNA and protein levels through a signaling pathway involving genistein-sensitive protein tyrosine kinases. Although an induction of PAI-1 mRNA was regulated primarily at the transcriptional levels, the regulatory region for PAI-1 promoter activity by hypoxia does not contain consensus HRE. Identification of a signaling cascade mediating the transcriptional response to hypoxia will facilitate our understanding of the molecular mechanisms responsible for endothelial dysfunction caused by hypoxia.
|
Acknowledgments |
|---|
This work was supported in part by a grant-in-aid for scientific research from the Ministry of Education, Science, Sport, and Culture of Japan and a grant from the Japan Cardiovascular Foundation (to M.K. and R.N.). We thank Dr Kuriyama-Fujii (Tohoku University, Sendai, Japan) for pBOS-EPAS.
Received August 12, 1999; accepted December 9, 1999.
|
References |
|---|
|
TopAbstractIntroductionMethodsResultsDiscussionReferences |
|---|
1. Dawson S, Henney A. The status of PAI-1 as a risk factor for arterial and thrombotic disease: a review. Atherosclerosis. 1992;95:105–117.[Medline] [Order article via Infotrieve]
2.
Lupu F, Bergonzelli GE, Heim DA, Cousin E, Genton CY,
Bachmann F, Kruithof EK. Localization and production of
plasminogen activator inhibitor-1
in human healthy and atherosclerotic arteries. Arterioscler
Thromb. 1993;13:1090–1100.
3. Philips M, Juul AG, Thorsen S. Human endothelial cells produce a plasminogen activator inhibitor and a tissue-type plasminogen activator-inhibitor complex. Biochim Biophys Acta. 1984;802:99–110.[Medline] [Order article via Infotrieve]
4.
Lee E, Vaughan DE, Parikh SH, Grodzinsky AJ, Libby P,
Lark MW, Lee RT. Regulation of matrix metalloproteinases and
plasminogen activator inhibitor-1
synthesis by plasminogen in cultured human vascular smooth
muscle cells. Circ Res. 1996;78:44–49.
5.
Reilly CF, McFall RC. Platelet-derived growth
factor and transforming growth factor-beta regulate
plasminogen activator inhibitor-1
synthesis in vascular smooth muscle cells. J Biol Chem. 1991;266:9419–9427.
6. Sprengers ED, Akkerman JW, Jansen BG. Blood platelet plasminogen activator inhibitor: two different pools of endothelial cell type plasminogen activator inhibitor in human blood. Thromb Haemost. 1986;55:325–329.[Medline] [Order article via Infotrieve]
7.
Antalis TM, Clark MA, Barnes T, Lehrbach PR, Devine
PL, Schevzov G, Goss NH, Stephens RW, Tolstoshev P. Cloning and
expression of a cDNA coding for a human monocyte-derived
plasminogen activator inhibitor.
Proc Natl Acad Sci U S A. 1988;85:985–989.
8.
Morton PA, Owensby DA, Sobel BE, Schwartz AL.
Catabolism of tissue-type plasminogen activator
by the human hepatoma cell line Hep G2: modulation by
plasminogen activator inhibitor
type 1. J Biol Chem. 1989;264:7228–7235.
9. Landin K, Stigendal L, Eriksson E, Krotkiewski M, Risberg B, Tengborn L, Smith U. Abdominal obesity is associated with an impaired fibrinolytic activity and elevated plasminogen activator inhibitor-1. Metabolism. 1990;39:1044–1048.[Medline] [Order article via Infotrieve]
10.
Robie LA, Booth NA, Brown AJ, Bennett B.
Inhibitors of fibrinolysis are elevated in
atherosclerotic plaque. Arterioscler Thromb Vasc Biol. 1996;16:539–545.
11.
Schleef RR, Bevilacqua MP, Sawdey M, Gimbrone MJ,
Loskutoff DJ. Cytokine activation of vascular
endothelium: effects on tissue-type
plasminogen activator and type 1
plasminogen activator inhibitor.
J Biol Chem. 1988;263:5797–5803.
12. Hajjar KA, Gavish D, Breslow JL, Nachman RL. Lipoprotein(a) modulation of endothelial cell surface fibrinolysis and its potential role in atherosclerosis. Nature. 1989;339:303–305.[Medline] [Order article via Infotrieve]
13. Feener EP, Northrup JM, Aiello LP, King GL. Angiotensin II induces plasminogen activator inhibitor-1 and -2 expression in vascular endothelial and smooth muscle cells. J Clin Invest. 1995;95:1353–1362.
14.
Sawdey M, Podor TJ, Loskutoff DJ. Regulation of type 1
plasminogen activator inhibitor
gene expression in cultured bovine aortic endothelial
cells: induction by transforming growth factor-beta,
lipopolysaccharide, and tumor necrosis factor-alpha.
J Biol Chem. 1989;264:10396–10401.
15.
Descheemaeker KA, Wyns S, Nelles L, Auwerx J, Ny T,
Collen D. Interaction of AP-1-, AP-2-, and Sp1-like proteins with two
distinct sites in the upstream regulatory region of the
plasminogen activator inhibitor-1
gene mediates the phorbol 12-myristate 13-acetate response.
J Biol Chem. 1992;267:15086–15091.
16. Fitzpatrick TE, Graham CH. Stimulation of plasminogen activator inhibitor-1 expression in immortalized human trophoblast cells cultured under low levels of oxygen. Exp Cell Res. 1998;245:155–162.[Medline] [Order article via Infotrieve]
17. Khan FA, Chitkara RK. Complications of acute respiratory failure. Postgrad Med. 1986;79:205–214.
18. Delaney ML, Onderdonk AB. Evaluation of the AnaeroPack system for growth of clinically significant anaerobes. J Clin Microbiol. 1997;35:558–562.[Abstract]
19. Booyse FM, Sedlak BJ, Rafelson ME Jr. Culture of arterial endothelial cells: characterization and growth of bovine aortic cells. Thromb Diath Haemorrh. 1975;34:825–839.[Medline] [Order article via Infotrieve]
20.
Doan N, Contreras A, Flynn J, Morrison J, Slots J.
Proficiencies of three anaerobic culture systems for
recovering periodontal pathogenic bacteria. J Clin
Microbiol. 1999;37:171–174.
21. Kamiya T, Kwon AH, Kanemaki T, Matsui Y, Uetsuji S, Okumura T, Kamiyama Y. A simplified model of hypoxic injury in primary cultured rat hepatocytes. In Vitro Cell Dev Biol Anim. 1998;34:131–137.[Medline] [Order article via Infotrieve]
22. Chomczynski P, Sacchi N. Single-step method of RNA isolation by acid guanidinium thiocyanate-phenol-chloroform extraction. Anal Biochem. 1987;162:156–159.[Medline] [Order article via Infotrieve]
23.
Bosma PJ, van den Berg EA, Kooistra T, Siemieniak DR,
Slightom JL. Human plasminogen activator
inhibitor-1 gene: promoter and structural gene
nucleotide sequences. J Biol Chem. 1988;263:9129–9141.
24. Nishida K, Harrison DG, Navas JP, Fisher AA, Dockery SP, Uematsu M, Nerem RM, Alexander RW, Murphy TJ. Molecular cloning and characterization of the constitutive bovine aortic endothelial cell nitric oxide synthase. J Clin Invest. 1992;90:2092–2096.
25.
Chen YQ, Su M, Walia RR, Hao Q, Covington JW, Vaughan
DE. Sp1 sites mediate activation of the plasminogen
activator inhibitor-1 promoter by glucose in
vascular smooth muscle cells. J Biol Chem. 1998;273:8225–8231.
26.
Ema M, Taya S, Yokotani N, Sogawa K, Matsuda Y,
Fujii-Kuriyama Y. A novel bHLH-PAS factor with close sequence
similarity to hypoxia-inducible factor 1alpha regulates the
VEGF expression and is potentially involved in lung and vascular
development. Proc Natl Acad Sci U S A. 1997;94:4273–4278.
27.
Goldberg MA, Dunning SP, Bunn HF. Regulation of the
erythropoietin gene: evidence that the oxygen sensor is a heme protein.
Science. 1988;242:1412–1415.
28.
Semenza GL, Jiang BH, Leung SW, Passantino R, Concordet
JP, Maire P, Giallongo A. Hypoxia response elements in the
aldolase A, enolase 1, and lactate dehydrogenase A gene promoters
contain essential binding sites for hypoxia-inducible factor 1.
J Biol Chem. 1996;271:32529–32537.
29.
Levitzki A, Gazit A. Tyrosine kinase inhibition: an
approach to drug development. Science. 1995;267:1782–1788.
30.
van Hinsbergh VW, Vermeer M, Koolwijk P, Grimbergen J,
Kooistra T. Genistein reduces tumor necrosis factor alpha-induced
plasminogen activator inhibitor-1
transcription but not urokinase expression in human
endothelial cells. Blood. 1994;84:2984–2991.
31. Uehara Y, Fukazawa H, Murakami Y, Mizuno S. Irreversible inhibition of v-src tyrosine kinase activity by herbimycin A and its abrogation by sulfhydryl compounds. Biochem Biophys Res Commun. 1989;163:803–809.[Medline] [Order article via Infotrieve]
32.
Anafi M, Gazit A, Zehavi A, Ben Neriah Y, Levitzki A.
Tyrphostin-induced inhibition of p210bcr-abl tyrosine kinase activity
induces K562 to differentiate. Blood. 1993;82:3524–3529.
33.
Yaish P, Gazit A, Gilon C, Levitzki A. Blocking of
EGF-dependent cell proliferation by EGF receptor kinase
inhibitors. Science. 1988;242:933–935.
34.
Wojta J, Jones RL, Binder BR, Hoover RL. Reduction in
pO2 decreases the fibrinolytic potential of
cultured bovine endothelial cells derived from
pulmonary arteries and lung microvasculature. Blood. 1988;71:1703–1706.
35. Bach RG, Arden ME, Recht PA, Levin R. Hypoxia modulates endothelial cell fibrinolytic potential. Circulation. 1988;78(suppl II):II-183.
36.
Shatos MA, Doherty JM, Stump DC, Thompson EA, Collen D.
Oxygen radicals generated during anoxia followed by
reoxygenation reduce the synthesis of tissue-type
plasminogen activator and
plasminogen activator inhibitor-1
in human endothelial cell culture. J Biol
Chem. 1990;265:20443–20448.
37. Gilles GM, Ditta GS, Helinski DR. A haemoprotein with kinase activity encoded by the oxygen sensor of Rhizobium meliloti. Nature. 1991;350:170–172.[Medline] [Order article via Infotrieve]
38. Mukhopadhyay D, Tsiokas L, Zhou XM, Foster D, Brugge JS, Sukhatme VP. Hypoxic induction of human vascular endothelial growth factor expression through c-Src activation. Nature. 1995;375:577–581.[Medline] [Order article via Infotrieve]
39.
Akiyama T, Ishida J, Nakagawa S, Ogawara H, Watanabe S,
Itoh N, Shibuya M, Fukami Y. Genistein, a specific
inhibitor of tyrosine-specific protein kinases.
J Biol Chem. 1987;262:5592–5595.
40.
Muller JM, Krauss B, Kaltschmidt C, Baeuerle PA, Rupec
RA. Hypoxia induces c-fos transcription via a
mitogen-activated protein kinase-dependent pathway.
J Biol Chem. 1997;272:23435–23439.
41.
Zidovetzki R, Wang J-L, Kim JA, Chen Peijia, Fisher M,
Hofman FM. Endothelin-1 enhances plasminogen
activator inhibitor-1 production by
human brain endothelial cells via protein kinase
C-dependent pathway. Arterioscler Thromb Vasc Biol. 1999;19:1768–1775.
42.
Johnson MR, Bruzdzinski CJ, Winograd SS, Gelehrter TD.
Regulatory sequences and protein-binding sites involved in the
expression of the rat plasminogen activator
inhibitor-1 gene. J Biol Chem. 1992;267:12202–12210.
This article has been cited by other articles:
 |
|
 |
|
  H. Kimura, X. Li, K. Torii, T. Okada, K. Kamiyama, D. Mikami, N. Takahashi, and H. Yoshida Dexamethasone enhances basal and TNF-{alpha}-stimulated production of PAI-1 via the glucocorticoid receptor regardless of 11{beta}-hydroxysteroid dehydrogenase 2 status in human proximal renal tubular cells Nephrol. Dial. Transplant., June 1, 2009; 24(6): 1759 - 1765. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 C.-L. Chung, J.-R. Sheu, H.-E. Liu, S.-C. Chang, Y.-C. Chou, W.-L. Chen, D.-S. Chou, and G. Hsiao Dynasore, a Dynamin Inhibitor, Induces PAI-1 Expression in MeT-5A Human Pleural Mesothelial Cells Am. J. Respir. Cell Mol. Biol., June 1, 2009; 40(6): 692 - 700. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
H. Kimura, X. Li, K. Torii, T. Okada, N. Takahashi, H. Fujii, S. Ishihara, and H. Yoshida A natural PPAR-{gamma} agonist, 15-deoxy-delta 12,14-prostaglandin J2, may act as an enhancer of PAI-1 in human proximal renal tubular cells under hypoxic and inflammatory conditions Nephrol. Dial. Transplant., August 1, 2008; 23(8): 2496 - 2503. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 D. Generali, S. B. Fox, A. Berruti, J. W. Moore, M. P. Brizzi, N. Patel, G. Allevi, S. Bonardi, S. Aguggini, A. Bersiga, et al. Regulation of Hepatocyte Growth Factor Activator Inhibitor 2 by Hypoxia in Breast Cancer Clin. Cancer Res., January 15, 2007; 13(2): 550 - 558. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 D. G. Peters, W. Ning, T. J. Chu, C. J. Li, and A. M. K. Choi Comparative SAGE analysis of the response to hypoxia in human pulmonary and aortic endothelial cells Physiol Genomics, September 14, 2006; 26(2): 99 - 108. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 L. H. Caramuru, A. A. Lopes, N. Y. Maeda, V. D. Aiello, and C. C. Filho Long-term Behavior of Endothelial and Coagulation Markers in Eisenmenger Syndrome Clinical and Applied Thrombosis/Hemostasis, April 1, 2006; 12(2): 175 - 183. [Abstract] [PDF]
|
|
|
|
 |
|
 H. Sato, M. Sato, H. Kanai, T. Uchiyama, T. Iso, Y. Ohyama, H. Sakamoto, J. Tamura, R. Nagai, and M. Kurabayashi Mitochondrial reactive oxygen species and c-Src play a critical role in hypoxic response in vascular smooth muscle cells Cardiovasc Res, September 1, 2005; 67(4): 714 - 722. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 C. H. Chau, C. A. Clavijo, H.-T. Deng, Q. Zhang, K.-J. Kim, Y. Qiu, A. D. Le, and D. K. Ann Etk/Bmx mediates expression of stress-induced adaptive genes VEGF, PAI-1, and iNOS via multiple signaling cascades in different cell systems Am J Physiol Cell Physiol, August 1, 2005; 289(2): C444 - C454. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
M. Sato, T. Tanaka, K. Maemura, T. Uchiyama, H. Sato, T. Maeno, T. Suga, T. Iso, Y. Ohyama, M. Arai, et al. The PAI-1 Gene as a Direct Target of Endothelial PAS Domain Protein-1 in Adenocarcinoma A549 Cells Am. J. Respir. Cell Mol. Biol., August 1, 2004; 31(2): 209 - 215. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
W. Ning, T. J. Chu, C. J. Li, A. M. K. Choi, and D. G. Peters Genome-wide analysis of the endothelial transcriptome under short-term chronic hypoxia Physiol Genomics, June 17, 2004; 18(1): 70 - 78. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 H. Akiyama, T. Tanaka, H. Itakura, H. Kanai, T. Maeno, H. Doi, M. Yamazaki, K. Takahashi, Y. Kimura, S. Kishi, et al. Inhibition of Ocular Angiogenesis by an Adenovirus Carrying the Human von Hippel-Lindau Tumor-Suppressor Gene In Vivo Invest. Ophthalmol. Vis. Sci., May 1, 2004; 45(5): 1289 - 1296. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 K. Niwano, M. Arai, K. Tomaru, T. Uchiyama, Y. Ohyama, and M. Kurabayashi Transcriptional Stimulation of the eNOS Gene by the Stable Prostacyclin Analogue Beraprost Is Mediated Through cAMP-Responsive Element in Vascular Endothelial Cells: Close Link Between PGI2 Signal and NO Pathways Circ. Res., September 19, 2003; 93(6): 523 - 530. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 J. Branger, B. van den Blink, S. Weijer, A. Gupta, S. J.H. van Deventer, C. E. Hack, M. P. Peppelenbosch, and T. van der Poll Inhibition of coagulation, fibrinolysis, and endothelial cell activation by a p38 mitogen-activated protein kinase inhibitor during human endotoxemia Blood, June 1, 2003; 101(11): 4446 - 4448. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 T. Ishibashi, T. Sakamoto, H. Ohkawara, K. Nagata, K. Sugimoto, S. Sakurada, N. Sugimoto, A. Watanabe, K. Yokoyama, N. Sakamoto, et al. Integral Role of RhoA Activation in Monocyte Adhesion-Triggered Tissue Factor Expression in Endothelial Cells Arterioscler Thromb Vasc Biol, April 1, 2003; 23(4): 681 - 687. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
T. Fink, A. Kazlauskas, L. Poellinger, P. Ebbesen, and V. Zachar Identification of a tightly regulated hypoxia-response element in the promoter of human plasminogen activator inhibitor-1 Blood, March 15, 2002; 99(6): 2077 - 2083. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
M. Sato, T. Tanaka, T. Maeno, Y. Sando, T. Suga, Y. Maeno, H. Sato, R. Nagai, and M. Kurabayashi Inducible Expression of Endothelial PAS Domain Protein-1 by Hypoxia in Human Lung Adenocarcinoma A549 Cells . Role of Src Family Kinases-dependent Pathway Am. J. Respir. Cell Mol. Biol., January 1, 2002; 26(1): 127 - 134. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 C. Depre, J. E. Tomlinson, R. K. Kudej, V. Gaussin, E. Thompson, S.-J. Kim, D. E. Vatner, J. N. Topper, and S. F. Vatner Gene program for cardiac cell survival induced by transient ischemia in conscious pigs PNAS, July 31, 2001; 98(16): 9336 - 9341. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
M. S. Pepper Role of the Matrix Metalloproteinase and Plasminogen Activator-Plasmin Systems in Angiogenesis Arterioscler Thromb Vasc Biol, July 1, 2001; 21(7): 1104 - 1117. [Abstract] [Full Text] [PDF]
|
|
| |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||